View Older Stories View More Recent Stories

Jul 27, 2023 06:01PM Genmab Updates 2023 Financial Guidance
Jul 20, 2023 06:22AM Genmab Announces Net Sales of DARZALEX® (daratumumab) for Second Quarter of 2023
May 19, 2023 12:34PM Genmab (GMAB) EPKINLY Approved by FDA as First and Only Bispecific Antibody to Treat Adults with R/R Diffuse Large B-cell Lymphoma
May 19, 2023 12:33PM EPKINLY™ (epcoritamab-bysp) Approved by U.S. Food and Drug Administration as the First and Only Bispecific Antibody to Treat Adults with Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (D
Apr 24, 2023 04:39AM Genmab To File Appeal in Its Second Arbitration Under License Agreement with Janssen
Apr 20, 2023 07:45PM Genmab Announces Initial Resolution of Its Second Arbitration Under License Agreement with Janssen
Apr 18, 2023 06:25AM Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2023
Apr 17, 2023 02:00AM Genmab and argenx Enter Partnership to Advance Antibody Therapies in Immunology and Oncology
Mar 14, 2023 09:00AM Stalkerware Grows 239% Worldwide Over the Past Three Years
Mar 9, 2023 10:00AM Avast Introduces Avast One Platinum
Feb 23, 2023 09:00AM LifeLock Offers Up to $3 Million in Identity Theft Coverage and Expanded Social Media Monitoring and Lock and Freeze Center Features
Feb 22, 2023 11:13AM Genmab (GMAB) Announces Initiation of Share Buy-Back Program
Feb 22, 2023 11:12AM Genmab Announces Initiation of Share Buy-Back Program
Feb 22, 2023 11:01AM Genmab Publishes 2022 Annual Report
Feb 9, 2023 08:00AM Avast Threat Report: Consumers Plagued with Refund Fraud, Tech Support Scams and Adware
Jan 24, 2023 06:27AM Genmab Announces Net Sales of DARZALEX® (daratumumab) for 2022
Dec 21, 2022 08:16AM AARP Services Announces New and Enhanced Benefits and Programs for AARP Members
Dec 20, 2022 08:00AM The European Commission selected the EU Digital Identity Wallet Consortium for the EU Digital Identity Wallet Pilots
Nov 3, 2022 12:45PM Genmab Improves Its 2022 Financial Guidance
Oct 18, 2022 06:35AM Genmab Announces Net Sales of DARZALEX® (daratumumab) for the Third Quarter of 2022
Oct 5, 2022 03:56PM Major Shareholder Announcement
Aug 8, 2022 12:34PM Genmab A/S (GMAB) Improves FY22 Financial Guidance
Aug 8, 2022 12:33PM Genmab Improves Its 2022 Financial Guidance
Aug 2, 2022 02:46PM Major Shareholder Announcement
Jul 20, 2022 01:03PM Major Shareholder Announcement
Jul 19, 2022 06:33AM Genmab Announces Net Sales of DARZALEX® (daratumumab) for the Second Quarter of 2022
Jul 18, 2022 10:02AM Genmab (GMAB) Announces That AbbVie (ABBV) Will Submit MAA to EMA for Epcoritamab for the Treatment of R/R DLBCL
Jul 18, 2022 10:01AM Genmab Announces That AbbVie Will Submit Marketing Authorization Application to European Medicines Agency for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Diffuse Large B-
Jul 11, 2022 11:28AM Major Shareholder Announcement
Jul 1, 2022 10:14AM Major Shareholder Announcement
Jun 30, 2022 02:25PM Genmab A/S (GMAB) to Submit BLA to FDA for Epcoritamab for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma
Jun 30, 2022 02:24PM Genmab to Submit Biologics License Application to U.S. Food and Drug Administration for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (LBCL)
Jun 20, 2022 10:35AM Major Shareholder Announcement
Jun 9, 2022 05:17PM Genmab Commences New Arbitration Under License Agreement With Janssen
Jun 1, 2022 12:21PM Major Shareholder Announcement
Apr 19, 2022 06:29AM Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2022
Apr 13, 2022 05:25PM Genmab and AbbVie Announce Topline Results for Epcoritamab (DuoBody®-CD3xCD20) From Phase 1/2 Trial in Patients with Relapsed/Refractory Large B-cell Lymphoma (LBCL)
Apr 7, 2022 07:44PM Genmab Announces the Initial Resolution of its Arbitration with Janssen Relating to their Daratumumab License Agreement
Feb 24, 2022 06:01AM Notice to Convene the Annual General Meeting of Genmab A/S
Feb 16, 2022 11:00AM Genmab Publishes 2021 Annual Report
Jan 25, 2022 06:30AM Genmab Announces Net Sales of DARZALEX® (daratumumab) for 2021
Jan 4, 2022 09:00AM Genmab and Synaffix Enter into License Agreement for ADC Technology
Nov 4, 2021 04:24PM Genmab Improves its 2021 Financial Guidance
Oct 19, 2021 06:37AM Genmab (GMAB) Announces Net Sales of DARZALEX® (daratumumab) for the Third Quarter of 2021
Oct 19, 2021 06:29AM Genmab Announces Net Sales of DARZALEX® (daratumumab) for the Third Quarter of 2021
Sep 21, 2021 02:22PM Capital Increase in Genmab as a Result of Employee Warrant Exercise
Sep 20, 2021 05:00PM Genmab and Seagen Announce FDA Accelerated Approval for TIVDAK™ (tisotumab vedotin-tftv) in Previously Treated Recurrent or Metastatic Cervical Cancer
Apr 9, 2021 04:00PM Genmab and Seagen Announce U.S. FDA Filing Acceptance for Priority Review of Tisotumab Vedotin Biologics License Application for Patients with Recurrent or Metastatic Cervical Cancer
Feb 10, 2021 04:05PM Genmab and Seagen Submit Tisotumab Vedotin Biologics License Application to the U.S. FDA for Patients with Recurrent or Metastatic Cervical Cancer
Sep 21, 2020 10:20AM Genmab and Seattle Genetics Present Data from Tisotumab Vedotin innovaTV 204 Pivotal Trial in Recurrent or Metastatic Cervical Cancer at ESMO Virtual Congress 2020
View More Recent Stories View Older Stories